-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program --
SOUTH SAN FRANCISCO,
At the meeting, one poster presentation will share new preclinical data from the Company’s interferon-α receptor (IFNAR) agonist program in chronic hepatitis B virus (HBV), currently in lead optimization. Additionally, an oral presentation will highlight data from the Phase 2 study of first-generation core inhibitor vebicorvir (VBR) in combination with nucleos(t)ide reverse transcriptase inhibitor (Nrtl) and Arbutus Biopharma’s AB-729 in virologically suppressed patients with hepatitis B e antigen negative chronic HBV.
“We look forward to presenting data at this year’s AASLD, The Liver Meeting®, featuring the exciting progress of our preclinical IFNAR agonist program and its potential to engage the interferon-α pathway with improved tolerability through an oral, liver-focused approach,” said
Details of the poster and oral presentations are as follows:
Interferon-α Receptor Agonist:
- Poster Presentation: In vitro and in vivo profiling of orally bioavailable small molecules inhibiting hepatitis B virus by mimicking interferon alpha
Presenter:Marc P. Windisch , PhD, Assembly Bio
Poster Number: 1474-C
Date and Time:November 10 , 12:00 PM–1:00 PM ET
Vebicorvir, Nrtl and AB-729:
- Oral Presentation: Preliminary Off-Treatment Responses Following 48 Weeks of Vebicorvir, Nucleos(t)ide Reverse Transcriptase Inhibitor, and AB-729 Combination in Virologically Suppressed Patients with Hepatitis B e Antigen Negative Chronic Hepatitis B: Analysis From an Open-Label Phase 2 Study
Presenter:Scott Fung , MD, FRCPC,Toronto General Hospital
Session: Hepatitis B: New Therapies for HBV and HDV
Date and Time:November 12 ,8:30 AM ET
Assembly Bio intends to make the presentations available on the “Events & Presentations” page in the “Investors” section of its website at www.assemblybio.com.
About Assembly Biosciences
Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to maintain financial resources necessary to continue its clinical studies and fund business operations; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the
Contacts
Investor and Corporate:
SVP, Investor Relations, Corporate Affairs and Alliance Management
(415) 738-2992
sryan@assemblybio.com
Media:
Sam Brown Inc.
Hannah Hurdle
(805) 338-4752
ASMBMedia@sambrown.com
Source:
2023 GlobeNewswire, Inc., source